Company news
Jasper Therapeutics, Inc. (NASDAQ:JSPR) news
Jasper Therapeutics, Inc. news releases on 6ix. Latest, Sep 15, 2026: Jasper Therapeutics Announces Key Regulatory and Clinical Appointments
Press releases & updates
Jasper Therapeutics Announces Key Regulatory and Clinical Appointments
September 15, 2026
Jasper Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
September 9, 2026
Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 17, 2026
Jasper Therapeutics Announces Merger with Kira Pharmaceuticals
July 16, 2026
Jasper Therapeutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value
May 31, 2026
Jasper Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 14, 2026
Jasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update
March 29, 2026
Jasper Therapeutics to Present at 46th Annual TD Cowen Healthcare Conference
February 24, 2026
Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria
January 8, 2026
Jasper Therapeutics Appoints Jeet Mahal as Chief Executive Officer to Lead Next Phase of Clinical Growth
January 7, 2026
Jasper Therapeutics Reports Positive Preliminary Data from ETESIAN Study of Briquilimab in Asthma and Findings from BEACON Study Internal Investigation
December 2, 2025
Jasper Therapeutics to Host an Investor Webinar on December 2nd to Present Preliminary Data from ETESIAN Study in Asthma and Findings from BEACON Study Investigation
December 1, 2025
Jasper Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 10, 2025
Jasper Therapeutics to Present at Upcoming Investor Conferences
November 4, 2025
Jasper Therapeutics Announces Pricing of $30 Million Public Offering of Common Stock, Pre-Funded Warrants and Common Warrants
September 18, 2025
Jasper Therapeutics Announces Proposed Public Offering of Common Stock, Pre-Funded Warrants and Common Warrants
September 18, 2025
Jasper Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
August 13, 2025
Jasper Therapeutics Announces Corporate Reorganization and Other Cost Cutting Measures to Extend Cash Runway
July 9, 2025
Jasper Therapeutics Reports Clinical Data Update from Briquilimab Studies in Chronic Spontaneous Urticaria
July 7, 2025
Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria
June 14, 2025
Jasper Therapeutics Announces Briquilimab Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress
June 3, 2025
Jasper Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 12, 2025
Jasper Therapeutics Presents Clinical and Preclinical Briquilimab Data at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
March 1, 2025
Jasper Therapeutics Announces Late-Breaking Briquilimab Presentation at the American Academy of Dermatology (AAD) Annual Meeting
February 28, 2025
Jasper Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate Update
February 27, 2025
Jasper Therapeutics to Present at Upcoming March Investor Conferences
February 25, 2025
Jasper Therapeutics Announces Briquilimab Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
February 9, 2025
Jasper Therapeutics Reports Positive Data from BEACON Study of Briquilimab in Chronic Spontaneous Urticaria
January 7, 2025
Jasper Therapeutics to Host Webinar to Present Preliminary Data from the BEACON Study of Briquilimab in Chronic Spontaneous Urticaria on January 8, 2025
January 5, 2025
Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a ETESIAN Clinical Study of Briquilimab in Asthma
December 1, 2024
Jasper Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
November 6, 2024
Jasper Therapeutics to Present Preclinical Briquilimab Data at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
October 23, 2024
Jasper Therapeutics Announces Further Expansion of Clinical Program in Chronic Spontaneous Urticaria
October 22, 2024
Jasper Therapeutics Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria
October 13, 2024
Jasper Therapeutics Announces Health Canada Clearance of Clinical Trial Application for Phase 1b/2a Study of Briquilimab in Asthma
September 9, 2024
Jasper Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Developments
August 12, 2024
Jasper Therapeutics Announces Appointment of Svetlana Lucas Ph.D., to its Board of Directors
June 18, 2024
Jasper Therapeutics Presents Data from Preclinical Briquilimab Study at the 2024 EHA Hybrid Congress
June 13, 2024
Jasper Therapeutics to Present Data on Briquilimab in Mast Cell Driven Diseases at the EAACI Congress 2024
May 29, 2024
Jasper Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Developments
May 13, 2024
Jasper Therapeutics Announces Briquilimab Development Program in Asthma
May 12, 2024
Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria
March 18, 2024
Jasper Therapeutics Reports Fiscal 2023 Financial Results and Recent Corporate Developments
March 3, 2024
Jasper Therapeutics Announces Pricing of $50 Million Underwritten Offering of Common Stock
February 5, 2024
Jasper Therapeutics Announces Preclinical Data Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
February 4, 2024
Jasper Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 1, 2024
Jasper Therapeutics, Inc. Announces Reverse Stock Split
January 1, 2024
Jasper Therapeutics Presents Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant in Oral Presentation at ASH 2023
December 9, 2023
Jasper Announces First Patient Dosed in Phase 1b/2a Clinical Study of Briquilimab in Chronic Spontaneous Urticaria
November 29, 2023
Jasper Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
November 8, 2023